In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
about
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalGlobal trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.Voriconazole in the management of nosocomial invasive fungal infections.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testingEpidemiology and management of cryptococcal meningitis: developments and challenges.Fluconazole resistance in cryptococcal disease: emerging or intrinsic?Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.Chemosensitization as a means to augment commercial antifungal agents.[First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
P2860
Q27012487-208FA445-8F85-4AC3-AECB-CF3926383108Q33859215-72B41B6D-131D-4590-844B-6D82F0A15172Q35004926-0FC9143C-4CC9-4FC7-AF98-D94991322327Q35166823-13F50F5A-895E-4F69-96AF-60EB98BB6B4BQ36364064-3017B383-F3EB-4AA0-8F79-645684C338D9Q36491819-3BA1738F-6CE5-4EC2-84D0-4E3FE9E65B0EQ37051529-1A6CB0C1-0121-40EA-8CF1-E54A6646B3ECQ37098995-40B41A85-35C3-4E0C-9CB6-A0D2E97D55F6Q38044487-CAA9CA93-DD07-4513-91F3-BFB83D71C502Q39481475-2EBEA5D7-7587-417B-9B0D-21CB6C846D38Q41643640-0CFDC620-6F6A-4E4C-8332-C7514F2BAD98Q41858553-DB7942DD-8FB7-4C9A-B33E-65B2AA0DACD1Q42141903-18816739-E918-496D-8BC7-35749EFC7758Q43140037-BB766C70-0D52-4981-A380-E2C56319810FQ46421581-B78FC04A-A9CF-48F3-BA74-952B14E9263D
P2860
In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
In vitro activity of amphoteri ...... ates from Africa and Cambodia.
@en
type
label
In vitro activity of amphoteri ...... ates from Africa and Cambodia.
@en
prefLabel
In vitro activity of amphoteri ...... ates from Africa and Cambodia.
@en
P2093
P1476
In vitro activity of amphoteri ...... ates from Africa and Cambodia.
@en
P2093
Adou-Bryn KD
Chandenier J
Richard-Lenoble D
Thérizol-Ferly M
P2888
P304
P356
10.1007/S10096-004-1136-2
P577
2004-05-13T00:00:00Z
P6179
1051195861